Navigating New Evidence in the Treatment of HER2-Expressing Metastatic Breast Cancer in Rural and Underserved Communities
June 30, 2023
June 30, 2024
This activity is jointly provided by Postgraduate Institute for Medicine and RME Collaborative.
This online program is recorded content from the live session at Oncology Congress and is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This activity is supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Seagen.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Over the past decades, the emergence of novel targeted therapies in combination with endocrine therapy has improved outcomes for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. However, oncology clinicians in rural and underserved areas are challenged to stay abreast of emerging evidence and face multiple barriers such as clinician shortages, long travel distances, and limited access to the latest treatments. In this activity, expert faculty will review the latest clinical data for treatment of HR-positive, HER2-negative breast cancer in the early and metastatic settings. Multidisciplinary strategies to reduce health disparities and address inequities in breast cancer across the care continuum will also be discussed.
This enduring activity is a recorded session from Oncology Congress that took place on April 1, 2023.
Upon completion of this activity, participants should be better able to:
- Explain the evolving role of HER2 testing in determining treatment selection in patients with HER2-expressing breast cancer
- Evaluate the efficacy and safety of current and emerging treatments for HER2-expressing metastatic breast cancer
- Integrate current guidelines and clinical evidence on sequencing of therapies into personalized treatment plans for patients with HER2-expressing metastatic breast cancer
- Identify evidence-based strategies for reducing disparities in breast cancer care access and treatment in rural and underserved settings
Harold J. Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine and RME Collaborative adhere to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Postgraduate Institute for Medicine requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies (commercial interests). All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to Postgraduate Institute for Medicine policy. Postgraduate Institute for Medicine is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Harold J. Burstein, MD, PhD, has no relevant financial relationships to disclose.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Postgraduate Institute for Medicine and RME Collaborative planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME credit, participants must:
- Read the CME/CE information, including learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
There is no fee for this educational activity.
For general information or questions about this activity, please contact RME Collaborative at 800-913-9370 or email@example.com.
For questions regarding the certification of this activity, please contact Postgraduate Institute for Medicine at firstname.lastname@example.org.